Opinion: Will the Biden administration use ‘march-in’ to protect prostate cancer patients from excessive drug prices?

Failing to grant a hearing on the Xtandi march-in petitions would signal that the federal government will continue to be a paper tiger when it comes to demonstrably unreasonable drug…

Click to view original post